$OCGN
Ocugen, Inc. Stock $ocgn

$ocgn Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000162828021005124 Filed on March 19, 2021

Income Statement

Concept	2020 Q4	2019 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.210M	$2.530M
YoY Change	-12.65%	17.67%
% of Gross Profit
Research & Development	$1.590M	$1.750M
YoY Change	-9.14%	-47.45%
% of Gross Profit
Depreciation & Amortization	$40.00K	$30.00K
YoY Change	33.33%	-66.67%
% of Gross Profit
Operating Expenses	$3.810M	$4.280M
YoY Change	-10.98%	-21.76%
Operating Profit
YoY Change
Interest Expense	-$170.0K	$16.69M
YoY Change	-101.02%	124.93%
% of Operating Profit
Other Income/Expense, Net	$180.0K	-$30.00K
YoY Change	-700.0%	-25.0%
Pretax Income	-$3.790M	$12.38M
YoY Change	-130.61%	-1609.76%
Income Tax
% Of Pretax Income
Net Earnings	-$3.790M	$12.38M
YoY Change	-130.61%	-1609.76%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$22.21K	$325.3K
COMMON SHARES
Basic Shares Outstanding	162.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.04M	$7.440M
YoY Change	223.12%	-52.12%
Cash & Equivalents	$24.04M	$7.444M
Short-Term Investments
Other Short-Term Assets	$1.840M	$8.320M
YoY Change	-77.88%	4737.21%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$25.88M	$15.77M
YoY Change	64.14%	712.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$633.0K	$222.5K
YoY Change	184.54%	-9.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$714.0K	$667.7K
YoY Change	6.93%	474.0%
Total Long-Term Assets	$1.498M	$1.041M
YoY Change	43.87%	103.13%
TOTAL ASSETS
Total Short-Term Assets	$25.88M	$15.77M
Total Long-Term Assets	$1.498M	$1.041M
Total Assets	$27.38M	$16.81M
YoY Change	62.88%	584.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$395.0K	$1.896M
YoY Change	-79.16%	-42.16%
Accrued Expenses	$2.930M	$2.270M
YoY Change	29.09%	61.83%
Deferred Revenue
YoY Change
Short-Term Debt	$234.0K	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$230.0K	$0.00
YoY Change
Total Short-Term Liabilities	$3.614M	$4.544M
YoY Change	-20.47%	-67.8%
LONG-TERM LIABILITIES
Long-Term Debt	$1.823M	$1.072M
YoY Change	70.04%	5.45%
Other Long-Term Liabilities	$0.00	$9.755K
YoY Change	-100.0%	-73.96%
Total Long-Term Liabilities	$2.212M	$1.245M
YoY Change	77.66%	18.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.614M	$4.544M
Total Long-Term Liabilities	$2.212M	$1.245M
Total Liabilities	$5.826M	$5.789M
YoY Change	0.64%	-61.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$73.30M	-$51.48M
YoY Change	42.39%	-264.8%
Common Stock	$1.841M	$527.5K
YoY Change	249.03%	-99.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$48.00K	$47.86K
YoY Change	0.28%
Treasury Stock Shares
Shareholders Equity	$21.55M	$11.02M
YoY Change
Total Liabilities & Shareholders Equity	$27.38M	$16.81M
YoY Change	62.88%	584.83%

Cashflow Statement

Concept	2020 Q4	2019 Q4
OPERATING ACTIVITIES
Net Income	-$3.790M	$12.38M
YoY Change	-130.61%	-1609.76%
Depreciation, Depletion And Amortization	$40.00K	$30.00K
YoY Change	33.33%	-66.67%
Cash From Operating Activities	-$4.280M	-$8.740M
YoY Change	-51.03%	25.94%
INVESTING ACTIVITIES
Capital Expenditures	-$250.0K	-$30.00K
YoY Change	733.33%	-57.14%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$250.0K	-$20.00K
YoY Change	1150.0%	-71.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.470M	910.0K
YoY Change	940.66%	-94.76%
NET CHANGE
Cash From Operating Activities	-4.280M	-8.740M
Cash From Investing Activities	-250.0K	-20.00K
Cash From Financing Activities	9.470M	910.0K
Net Change In Cash	4.940M	-7.850M
YoY Change	-162.93%	-175.85%
FREE CASH FLOW
Cash From Operating Activities	-$4.280M	-$8.740M
Capital Expenditures	-$250.0K	-$30.00K
Free Cash Flow	-$4.030M	-$8.710M
YoY Change	-53.73%	26.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001372299
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y
CY2020Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-36751
CY2020	dei	Entity Registrant Name EntityRegistrantName	OCUGEN, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3522315
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	263 Great Valley Parkway
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Malvern,
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19355
CY2020	dei	City Area Code CityAreaCode	484
CY2020	dei	Local Phone Number LocalPhoneNumber	328-4701
CY2020	dei	Security12b Title Security12bTitle	Common Stock
CY2020	dei	Trading Symbol TradingSymbol	OCGN
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	28600000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	188088860	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24039325	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7444052	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1838357	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1322167	USD
CY2020Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	0	USD
CY2019Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	7000000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	25877682	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	15766219	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	632967	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	222464	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151226	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151016	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	714477	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	667747	USD
CY2020Q4	us-gaap	Assets Assets	27376352	USD
CY2019Q4	us-gaap	Assets Assets	16807446	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	395034	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1895613	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2930395	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2270045	USD
CY2020Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	234119	USD
CY2019Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	44248	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	172310	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9755	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	205991	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3613551	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4543959	USD
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	7	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	7	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	7	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	7	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	184133384	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52746728	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	184011884	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52625228	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1841334	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	527467	USD
CY2019Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	121500	shares
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	121500	shares
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	47864	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	47864	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93058748	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	62018632	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73301777	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51479824	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	21550441	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11018411	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	389317	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	163198	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1823043	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1072123	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9755	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2212360	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1245076	USD
CY2020Q4	us-gaap	Liabilities Liabilities	5825911	USD
CY2019Q4	us-gaap	Liabilities Liabilities	5789035	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2019	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-3187380	USD
CY2020	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	0	USD
CY2019	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	-341136	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	1065	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	1214	USD
CY2020	us-gaap	Interest Expense InterestExpense	720963	USD
CY2019	us-gaap	Interest Expense InterestExpense	1767836	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	182662	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-784873	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-537236	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6080011	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-21821953	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20242630	USD
CY2020	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	12546340	USD
CY2019	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34368293	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20242630	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112236110	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13893819	shares
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.46
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-21821953	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20242630	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-451	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21821953	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27376352	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16807446	USD
CY2020	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	42620	USD
CY2019	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	USD
CY2020	us-gaap	Revenues Revenues	42620	USD
CY2019	us-gaap	Revenues Revenues	0	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6353287	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	8085522	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	7000000	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7974050	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6077097	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	21327337	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	14162619	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-21284717	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-14162619	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20243081	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-12709539	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	884089	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13979788	USD
CY2019	ocgn	Reclassification Of Warrants From Liability To Equity ReclassificationOfWarrantsFromLiabilityToEquity	11255740	USD
CY2019	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	47864	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-451	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20242630	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11018411	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	660317	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-4977876	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-21821953	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	21550441	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-21821953	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-20242630	USD
CY2020	us-gaap	Depreciation Depreciation	102110	USD
CY2019	us-gaap	Depreciation Depreciation	60608	USD
CY2020	ocgn	Non Cash Interest Expense NonCashInterestExpense	720963	USD
CY2019	ocgn	Non Cash Interest Expense NonCashInterestExpense	1733521	USD
CY2020	ocgn	Noncash Lease Expense NoncashLeaseExpense	189424	USD
CY2019	ocgn	Noncash Lease Expense NoncashLeaseExpense	250361	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	7000000	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2019	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-3187380	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	660317	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	884089	USD
CY2020	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	0	USD
CY2019	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	-341136	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	349409	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-4803	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	369846	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1007367	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-540847	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1628621	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	104000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	227172	USD
CY2020	ocgn	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-195489	USD
CY2019	ocgn	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-249389	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14708730	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16893281	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	306825	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29446	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2327273	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-306825	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2356719	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	23856	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	25866	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37822025	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1183034	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1477806	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	921415	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6800000	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	5740	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	99202	USD
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	5625000	USD
CY2019	us-gaap	Repayments Of Debt RepaymentsOfDebt	5290000	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	47864	USD
CY2020	ocgn	Proceeds From Pre Merger Financing Financing Activities ProceedsFromPreMergerFinancingFinancingActivities	0	USD
CY2019	ocgn	Proceeds From Pre Merger Financing Financing Activities ProceedsFromPreMergerFinancingFinancingActivities	22546353	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31611038	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25066455	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16595483	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5816455	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7595068	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1778613	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24190551	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7595068	USD
CY2020	us-gaap	Notes Issued1 NotesIssued1	5625000	USD
CY2019	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	331218	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	213625	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2020	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2019	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	13979788	USD
CY2020	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	179599	USD
CY2019	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	470356	USD
CY2020	ocgn	Noncash Or Part Noncash Amount Of Deferred Transaction Cost NoncashOrPartNoncashAmountOfDeferredTransactionCost	4029	USD
CY2019	ocgn	Noncash Or Part Noncash Amount Of Deferred Transaction Cost NoncashOrPartNoncashAmountOfDeferredTransactionCost	1150000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2020	ocgn	Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2019	ocgn	Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction	2252795	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen, Inc., together with its wholly owned subsidiaries (“Ocugen” or the “Company”), is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The Company is located in Malvern, Pennsylvania.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen is co-developing COVAXIN, a whole-virion inactivated COVID-19 vaccine candidate, with Bharat Biotech International Limited ("Bharat Biotech") for the U.S. market. COVAXIN is being developed to prevent COVID-19 infection in humans and is formulated with the inactivated SARS-CoV-2 virus, an antigen, and an adjuvant. In February 2021, the Company entered into a Co-Development, Supply and Commercialization Agreement (the "Covaxin Agreement") with Bharat Biotech, pursuant to which the Company obtained an exclusive right and license under certain of Bharat Biotech's intellectual property rights, with the right to grant sublicenses to develop, manufacture, and commercialize COVAXIN for the prevention of COVID-19 in humans in the United States, its territories and possessions (the “Ocugen Covaxin Territory”). COVAXIN has been granted approval for emergency use in India. A Phase 3 clinical trial is ongoing in India. The Company is currently evaluating the clinical and regulatory path for COVAXIN in the United States including obtaining Emergency Use Authorization ("EUA") from the U.S. Food and Drug Administration (the "FDA") and, eventually, biologic license application (“BLA”) approval in the U.S. market, as well as the Company's commercialization strategy, if authorized or approved. See Note 16 for additional information about the terms, rights, and obligations under the Covaxin Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen is developing a breakthrough modifier gene therapy platform to generate therapies designed to fulfill unmet medical needs in the area of retinal diseases, including inherited retinal diseases ("IRDs") and dry age-related macular degeneration ("AMD"). Ocugen's modifier gene therapy platform is based on nuclear hormone receptors (“NHRs”), which have the potential to restore homeostasis, the basic biological processes in the retina. Unlike single-gene replacement therapies, which only target one genetic mutation, Ocugen believes that its gene therapy platform, through its use of NHRs, represents a novel approach in that it may address multiple retinal diseases with one product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCU400 is the Company's first product candidate being developed with the Company's modifier gene therapy platform. OCU400 is a novel gene therapy product candidate with the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse IRDs, including retinitis pigmentosa ("RP") and leber congenital amaurosis ("LCA"). OCU400 has received four Orphan Drug Designations from the FDA for the treatment of certain disease genotypes: nuclear receptor subfamily 2 group E member 3 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), centrosomal protein 290 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CEP290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), rhodopsin ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), and phosphodiesterase 6B ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PDE6ß</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">") mutation-associated inherited retinal degenerations. Ocugen is planning to initiate two Phase 1/2a clinical trials for OCU400 in the United States in the second half of 2021. OCU400 additionally received Orphan Medicinal Product Designation from the European Commission, based on the recommendation of the European Medicines Agency, for RP and LCA in February 2021, which Ocugen believes further supports the broad spectrum application of OCU400 to treat many IRDs. Ocugen is currently evaluating options to commence OCU400 clinical trials in Europe in 2022. Ocugen's second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RORA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">") for the treatment of dry AMD. This candidate is currently in preclinical development. Ocugen is planning to initiate a Phase 1/2a clinical trial for OCU410 in 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen is also conducting preclinical development for its biologic product candidate, OCU200. OCU200 is a novel fusion protein designed to treat diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen had a pre-Investigational New Drug ("IND") meeting with the FDA in November 2020 and received guidance on IND-enabling preclinical studies to support the Phase 1/2a study. Ocugen expects to initiate IND-enabling preclinical studies for OCU200 in 2021. Ocugen plans to initiate a Phase 1/2a clinical trial for OCU200 in 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen was developing OCU300, a small molecule therapeutic for the treatment of symptoms associated with ocular graft-versus-host disease. The Phase 3 clinical trial for OCU300 was discontinued in 2020 based on results of a pre-planned interim sample size analysis conducted by an independent Data Monitoring Committee, which indicated the trial was unlikely to meet its co-primary endpoints upon completion. Ocugen is no longer pursuing the development of this product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Histogenics</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2019, the Company, which was formerly known as Histogenics Corporation ("Histogenics"), completed a reverse merger (the "Merger") with Ocugen OpCo, Inc. ("OpCo") in accordance with the terms of the Agreement and Plan of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger and Reorganization, dated as of April 5, 2019, by and among OpCo, Restore Merger Sub, Inc., the Company's wholly owned subsidiary ("Merger Sub"), and the Company, as amended (the "Merger Agreement") pursuant to which Merger Sub merged with and into OpCo, with OpCo surviving as the Company's wholly owned subsidiary. Immediately after completion of the Merger, the Company changed its name to Ocugen, Inc. and the business previously conducted by OpCo became the business conducted by the Company. OpCo is deemed to be the accounting acquirer. Accordingly, the historical financial statements of OpCo became the Company’s historical financial statements, including the comparative prior periods. See Note 3 for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern Consideration</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) assuming the Company will continue as a going concern. As of December 31, 2020, the Company had cash, cash equivalents, and restricted cash of approximately $24.2 million, and since that date the Company has received net proceeds of $4.8 million from the sale of the Company's common stock in an at-the-market offering (“ATM") commenced in August 2020 and net proceeds of $21.2 million from the sale of the Company's common stock in a registered direct offering (the "Registered Direct Offering"). See Note 9 for additional information about the August 2020 ATM. See Note 16 for additional information about the Registered Direct Offering. As a result of the Company's cash, cash equivalents, and restricted cash balance as of December 31, 2020 and the net proceeds received subsequent to December 31, 2020 from the August 2020 ATM and the Registered Direct Offering, the Company believes that its cash, cash equivalents, and restricted cash will enable the Company to fund its operating expenses and capital expenditure requirements through at least one year from the date the audited consolidated financial statements are issued.</span></div>
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24200000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the estimation of clinical trial accruals, warrant transactions, asset held for sale, and the valuation of debt and equity instruments, including embedded derivatives, and stock-based compensation.</span></div>
CY2020Q4	ocgn	Collaborative Arrangement Number Of Agreements CollaborativeArrangementNumberOfAgreements	2	agreement
CY2019Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	7000000.0	USD
CY2020Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	7000000.0	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24039325	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7444052	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151226	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151016	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24190551	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7595068	USD
CY2020Q4	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P5Y
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	858664	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	348512	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	225697	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	126048	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	632967	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	222464	USD
CY2019	us-gaap	Depreciation Depreciation	100000	USD
CY2020	us-gaap	Depreciation Depreciation	100000	USD
CY2020Q4	ocgn	Lessee Operating Lease Number Of Renewal Terms LesseeOperatingLeaseNumberOfRenewalTerms	1	segment
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	189424	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	250361	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	84790	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	79700	USD
CY2020	us-gaap	Lease Cost LeaseCost	274214	USD
CY2019	us-gaap	Lease Cost LeaseCost	330061	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	433649	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	344574	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	44248	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	172310	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	389317	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	163198	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	433565	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	335508	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y10M24D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.046
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	61688	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	69399	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	71502	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	73605	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	75708	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	157725	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	509627	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	76062	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	433565	USD
CY2020	us-gaap	Payments For Rent PaymentsForRent	1400000	USD
CY2018Q2	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P5Y
CY2018Q2	us-gaap	Lessee Finance Lease Discount Rate LesseeFinanceLeaseDiscountRate	0.076
CY2020Q4	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	512026	USD
CY2019Q4	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	271322	USD
CY2020Q4	ocgn	Accrued Liabilities Clinical AccruedLiabilitiesClinical	117012	USD
CY2019Q4	ocgn	Accrued Liabilities Clinical AccruedLiabilitiesClinical	421788	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	405001	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	917568	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	963117	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	624420	USD
CY2020Q4	ocgn	Accrued Severance Related Liabilities Current AccruedSeveranceRelatedLiabilitiesCurrent	711596	USD
CY2019Q4	ocgn	Accrued Severance Related Liabilities Current AccruedSeveranceRelatedLiabilitiesCurrent	0	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	221643	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	34947	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2930395	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2270045	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	2057162	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	1072123	USD
CY2019Q2	ocgn	Common Stock Shares Agreed To Be Sold Stock Subscription Agreement CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement	100000	shares
CY2019Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.41
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	900000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	13000000.0	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	234119	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	187296	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	1500000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1921415	USD
CY2018Q4	ocgn	Number Of Former Employees With Warrants NumberOfFormerEmployeesWithWarrants	2	employee
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	660317	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	884089	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1100000	USD
CY2020Q4	ocgn	Number Of Equity Compensation Plans NumberOfEquityCompensationPlans	2	equityCompensationPlan
CY2019	ocgn	Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Shares To Be Issue Percentage ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage	0.04
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.34
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.84
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	500000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1000000.0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-21800000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20200000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.075
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.053
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.028
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.032
CY2020	ocgn	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	0.010
CY2019	ocgn	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	0.081
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.011
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.029
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.314
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.243
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35714104	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31575288	USD
CY2020Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	7298024	USD
CY2019Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	7298052	USD
CY2020Q4	ocgn	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	11234623	USD
CY2019Q4	ocgn	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	11234751	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	397982	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	166611	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2285247	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	555352	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1290212	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1123100	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2541244	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1926677	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	60886702	USD
CY2020Q4	ocgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	125266	USD
CY2019Q4	ocgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	96895	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	53976726	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	60761412	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53877168	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	125290	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	99558	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	125290	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	99558	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6900000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303050	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	303050	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303050	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303050	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	300000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-21821953	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20242630	USD
CY2020	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	12546340	USD
CY2019	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34368293	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20242630	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112236110	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13893819	shares
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.46
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5094450	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10375134	shares

Files In Submission

Name	View Source	Status
0001628280-21-005124-index-headers.html	Edgar Link	pending
0001628280-21-005124-index.html	Edgar Link	pending
0001628280-21-005124.txt	Edgar Link	pending
0001628280-21-005124-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ocgn-20201230x10kxex41.htm	Edgar Link	pending
ocgn-20201231.htm	Edgar Link	pending
ocgn-20201231.xsd	Edgar Link	pending
ocgn-20201231x10kxex1012.htm	Edgar Link	pending
ocgn-20201231x10kxex107.htm	Edgar Link	pending
ocgn-20201231x10kxex211.htm	Edgar Link	pending
ocgn-20201231x10kxex231.htm	Edgar Link	pending
ocgn-20201231x10kxex311.htm	Edgar Link	pending
ocgn-20201231x10kxex312.htm	Edgar Link	pending
ocgn-20201231x10kxex321.htm	Edgar Link	pending
ocgn-20201231x10kxex35.htm	Edgar Link	pending
ocgn-20201231x10kxex48.htm	Edgar Link	pending
ocgn-20201231_cal.xml	Edgar Link	unprocessable
ocgn-20201231_def.xml	Edgar Link	unprocessable
ocgn-20201231_g1.jpg	Edgar Link	pending
ocgn-20201231_g10.jpg	Edgar Link	pending
ocgn-20201231_g11.jpg	Edgar Link	pending
ocgn-20201231_g12.jpg	Edgar Link	pending
ocgn-20201231_g2.jpg	Edgar Link	pending
ocgn-20201231_g3.jpg	Edgar Link	pending
ocgn-20201231_g4.jpg	Edgar Link	pending
ocgn-20201231_g5.jpg	Edgar Link	pending
ocgn-20201231_g6.jpg	Edgar Link	pending
ocgn-20201231_g7.jpg	Edgar Link	pending
ocgn-20201231_g8.jpg	Edgar Link	pending
ocgn-20201231_g9.jpg	Edgar Link	pending
ocgn-20201231_htm.xml	Edgar Link	completed
ocgn-20201231_lab.xml	Edgar Link	unprocessable
ocgn-20201231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OCGN
Ocugen, Inc. Stock $ocgn

2020 Q4 Form 10-K Financial Statement

#000162828021005124 Filed on March 19, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN Ocugen, Inc. Stock $ocgn

2020 Q4 Form 10-K Financial Statement

#000162828021005124 Filed on March 19, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN
Ocugen, Inc. Stock $ocgn